The Implantable Infusion Pumps Market Size is valued at USD16.24 Billion in 2023 and is predicted to reach USD 23.96 Billion by the year 2031 at a 5.15 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The improvements in medical device technology and favorable high-tech medical treatments are expanding the market's future growth.
- As healthcare spending and investments in healthcare infrastructure continue to rise, implantable infusion pumps are becoming more popular.
- North America dominated the market and accounted for a global revenue share in 2023.
- High treatment costs and a lack of knowledge might slow this industry's growth.
The global implantable infusion pumps market is segmented on the basis of application and region. Based on the application, the market is divided into malignant pain management, cancer treatment, non-malignant pain management, and spasticity treatment. Based on region, the market is studied across North America, Asia-Pacific, Europe, Latin America and Middle East & Africa. Among that, North America held the largest share of the market, followed by Europe. On the other hand, Asia-Pacific is expected to dominate the market during the analysis of the forecast period.
Recent Developments:
In Nov 2022, Medtronic introduced the first and only infusion set for insulin pumps in the world, which has increased wear duration by seven days in the United States. Typically, an insulin pump supplied insulin to the body via tubing known as the infusion set, which required replacement every two to three days
Competitive Landscape
Some of The Key Players in The Implantable Infusion Pumps Market:
- Codman & Shurtleff, Inc (Johnson & Johnson)
- I-Flow Corp/Hylard Health
- Flowobix Medical, Inc.
- Medtronic
- Tricumed Medizintechnik GmbH.
- Debiotech SA
- Eksigent Technologies LLC
- InBrain Pharma SAS
- Intarcia Therapeutics Inc
- Other Prominent Players
The Implantable Infusion Pumps Market Report Scope
Report Attribute |
Specifications |
Market Size Value In 2023 |
USD 16.24 Billion |
Revenue Forecast In 2031 |
USD 23.96 Billion |
Growth Rate CAGR |
CAGR of 5.15 % from 2024 to 2031 |
Quantitative Units |
Representation of revenue in US$ Billion, Volume (Unit), and CAGR from 2024 to 2031 |
Historic Year |
2019 to 2023 |
Forecast Year |
2024-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Application, By Product Type, By End-User |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
Codman & Shurtleff, Inc (Johnson & Johnson), I-Flow Corp/Hylard Health, Flowobix Medical, Inc., Medtronic, Tricumed Medizintechnik GmbH., Debiotech SA, Eksigent Technologies LLC, InBrain Pharma SAS, Intarcia Therapeutics Inc., and others |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |